Document Detail


Weight gain during insulin therapy in patients with type 2 diabetes mellitus.
MedLine Citation:
PMID:  15315867     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In patients with diabetes, the benefits of tight glycemic control are unequivocal--delayed onset and progression of complications such as retinopathy, nephropathy, and neuropathy. However, intensive therapy with insulin and some oral antidiabetic agents come at the price of weight gain, a condition that can prevent attainment of tight glycemic goals and probably limits success of treatment. Insulin-related weight gain has been attributed to anabolic effects of insulin, appetite increases, and reduction of glycosuria. Use of metformin in combination with insulin is commonly recommended as a way to limit weight gain in patients with type 2 diabetes, and other new oral therapies and insulin analogs may also provide weight-control advantages. Lifestyle interventions (patient education about diet and exercise) promote weight loss in the short-term, but have not sustained weight control over long-term intervals. For lasting weight control, such interventions may need to continue throughout the course of treatment. Likewise, weight-loss agents, such as sibutramine and orlistat promote short-term weight loss, but no follow-up studies have yet demonstrated that this loss can be maintained for 5 years or longer. Bariatric surgery is the only treatment recognized to have lasting effects on weight control, but its use is limited at present to those who are morbidly obese.
Authors:
Simon Heller
Related Documents :
10837697 - Current status and future prospects of parenteral insulin regimens, strategies and deli...
10546007 - Continuous subcutaneous insulin infusion. a new way to lower risk of severe hypoglycemi...
24823457 - Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 d...
3931457 - Review of glyburide after one year on the market.
7051947 - Effects of exogenous glucagon on concentrations of glucose, fructose and insulin in pla...
2194907 - Update on diabetic nephropathy in niddm.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Diabetes research and clinical practice     Volume:  65 Suppl 1     ISSN:  0168-8227     ISO Abbreviation:  Diabetes Res. Clin. Pract.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-18     Completed Date:  2005-02-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8508335     Medline TA:  Diabetes Res Clin Pract     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  S23-7     Citation Subset:  IM    
Affiliation:
University of Sheffield, Section of Medicine, Clinical Sciences Centre, Sheffield S102TN, UK. s.heller@sheffield.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose / metabolism
Diabetes Mellitus, Type 2 / drug therapy*,  physiopathology*,  rehabilitation
Exercise
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use*
Obesity / prevention & control
Patient Education as Topic*
Weight Gain / physiology*
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Hypoglycemic Agents; 11061-68-0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Managing obesity and glycemic control in insulin-using patients: clinical relevance and practice rec...
Next Document:  Controlling diabetes: the need for intensive therapy and barriers in clinical management.